EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

Aaron Waxman iD, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Peter Engel, Abubakr Bajwa, Ashwin Ravichandran, Jeremy Feldman, Amy Hajari Case, Rahul G Argula, Victor Tapson, Peter Smith, Chunqin Deng iD und 2 weitere

European Respiratory Journal · 2023-06 · 61 (6) · 2202414

DOI: 10.1183/13993003.02414-2022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 20.04.2023. Verfasst von Aaron Waxman und 13 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, MA, USA abwaxman@bwh.harvard.edu. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Lung Diseases, Interstitial. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: United Therapeutics Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). The open-label extension (OLE) evaluated long-term effects of inhaled treprostinil in PH-ILD.

Methods

Of 258 eligible patients, 242 enrolled in the INCREASE OLE and received inhaled treprostinil. Assessments included 6MWD, pulmonary function testing, N-terminal pro-brain natriuretic peptide (NT-proBNP), quality of life and adverse events. Hospitalisations, exacerbations of underlying lung disease and death were recorded.

Results

At INCREASE OLE baseline, patients had a median age of 70 years and a mean 6MWD of 274.2 m; 52.1% were male. For the overall population, the mean 6MWD at week 52 was 279.1 m and the mean change from INCREASE RCT baseline was 3.5 m (22.1 m for the prior inhaled treprostinil arm and −19.5 m for the prior placebo arm); the median NT-proBNP decreased from 389 pg·mL −1 at RCT baseline to 359 pg·mL −1 at week 64; and the absolute (% predicted) mean forced vital capacity change from RCT baseline to week 64 was 51 mL (2.8%). Patients who received inhaled treprostinil versus placebo in the RCT had a 31% lower relative risk of exacerbation of underlying lung disease in the OLE (hazard ratio 0.69 (95% CI 0.49–0.97); p=0.03). Adverse events leading to drug discontinuation occurred in 54 (22.3%) patients.

Conclusions

These results support the long-term safety and efficacy of inhaled treprostinil in patients with PH-ILD, and are consistent with the results observed in the INCREASE RCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryLung Diseases, InterstitialAgedFemaleHumansMaleAntihypertensive AgentsEpoprostenolQuality of LifeTreatment Outcome

Substanzen

Antihypertensive AgentsEpoprostenoltreprostinil

Autor:innen und Institutionen

  • Brigham and Women's Hospital, Boston, MA, USA abwaxman@bwh.harvard.edu.
  • University of South Florida, Tampa, FL, USA.
  • University of Minnesota, Minneapolis, MN, USA.
  • Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, OH, USA.
  • Ascension Medical Group, Jacksonville, FL, USA.
  • Ascension Medical Group, Indianapolis, IN, USA.

ORCID-Profile: Aaron Waxman, Chunqin Deng, Steven D Nathan

Förderung

  • United Therapeutics Corporation

Zitieren

APA

Waxman, A., Restrepo-Jaramillo, R., Thenappan, T., Engel, P., Bajwa, A., Ravichandran, A., Feldman, J., Hajari Case, A., Argula, R. G., Tapson, V., Smith, P., Deng, C., Shen, E., & Nathan, S. D. (2023). Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. European Respiratory Journal, 61(6), 2202414. https://doi.org/10.1183/13993003.02414-2022

Vancouver

Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. European Respiratory Journal. 2023;61(6):2202414. doi:10.1183/13993003.02414-2022

BibTeX
@article{Waxman2023,
  author = {Waxman, Aaron and Restrepo-Jaramillo, Ricardo and Thenappan, Thenappan and Engel, Peter and Bajwa, Abubakr and Ravichandran, Ashwin and Feldman, Jeremy and Hajari Case, Amy and Argula, Rahul G and Tapson, Victor and Smith, Peter and Deng, Chunqin and Shen, Eric and Nathan, Steven D},
  title = {Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {6},
  pages = {2202414},
  doi = {10.1183/13993003.02414-2022}
}
Kostenlos starten →